Lipid-lowering therapy in high cardiovascular risk patients during COVID-19 pandemic: keep focused on the target

Area of Science:

• Cardiology
• Infectious Diseases
• Pharmacology

Background:

• COVID-19 (COrona VIrus Disease) disproportionately affects patients with cardiovascular disease (CVD) and related risk factors like hypertension and diabetes.
• The prognostic implications of pre-existing cardiovascular conditions in COVID-19 patients are significant, often leading to poorer outcomes.
• Early in the pandemic, the role and safety of ongoing cardiovascular therapies, such as Angiotensin-Converting Enzyme inhibitors, in COVID-19 patients remained a subject of debate.

Discussion:

• Investigating the complex interplay between SARS-CoV-2 infection and the cardiovascular system is crucial.
• Understanding how existing cardiovascular conditions influence COVID-19 severity and patient prognosis is essential for clinical management.
• Evaluating the potential impact of cardiovascular medications on COVID-19 outcomes requires careful consideration.

Key Insights:

• Cardiovascular disease and its risk factors are linked to a worse prognosis in COVID-19 patients.
• The use of cardiovascular therapies during SARS-CoV-2 infection warrants further investigation due to potential effects on disease progression.
• Arterial hypertension and diabetes are significant comorbidities associated with adverse COVID-19 outcomes.

Outlook:

• Further research is needed to clarify the specific effects of various cardiovascular therapies on COVID-19 prognosis.
• Developing evidence-based guidelines for managing cardiovascular patients during viral pandemics is a priority.
• Long-term studies will be vital to understand the full spectrum of cardiovascular complications and treatment implications post-COVID-19.